{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:02:45Z","timestamp":1789750965767,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"am","delay-in-days":301,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005155","name":"Azrieli Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG054473"],"award-info":[{"award-number":["R01AG054473"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB021155"],"award-info":[{"award-number":["R01EB021155"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012171","name":"Ontario Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["DE-SC0012484"],"award-info":[{"award-number":["DE-SC0012484"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["R01EB021155"],"award-info":[{"award-number":["R01EB021155"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Fluorine Chemistry"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jfluchem.2021.109760","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T15:02:32Z","timestamp":1613919752000},"page":"109760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of GSK-3"],"prefix":"10.1016","volume":"245","author":[{"given":"Cassis","family":"Varlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew V.","family":"Mossine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Bernard-Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.H.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2087-5125","authenticated-orcid":false,"given":"Neil","family":"Vasdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jfluchem.2021.109760_bib0005","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","article-title":"Molecular cloning and expression of glycogen synthase kinase-3\/factor A","volume":"9","author":"Woodgett","year":"1990","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.jfluchem.2021.109760_bib0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7150\/thno.14334","article-title":"Glycogen Synthase Kinase-3 (GSK-3)-Targeted therapy and imaging","volume":"6","author":"Pandey","year":"2016","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.jfluchem.2021.109760_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tibs.2003.12.004","article-title":"The glamour and gloom of glycogen synthase kinase-3","volume":"29","author":"Jope","year":"2004","journal-title":"Trends Biochem. Sci."},{"issue":"9","key":"10.1016\/j.jfluchem.2021.109760_bib0020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tips.2004.07.006","article-title":"Pharmacological inhibitors of glycogen synthase kinase 3","volume":"25","author":"Meijer","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jfluchem.2021.109760_bib0025","doi-asserted-by":"crossref","first-page":"189246","DOI":"10.4061\/2011\/189246","article-title":"GSK-3 in neurodegenerative diseases","volume":"2011","author":"Lei","year":"2011","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"issue":"9","key":"10.1016\/j.jfluchem.2021.109760_bib0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0165-6147(03)00206-2","article-title":"Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes","volume":"24","author":"Jope","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"issue":"15","key":"10.1016\/j.jfluchem.2021.109760_bib0035","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.2174\/15680266113139990138","article-title":"Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer\u2019s disease","volume":"13","author":"Martinez","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jfluchem.2021.109760_bib0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fnmol.2011.00032","article-title":"GSK-3 inhibitors: preclinical and clinical focus on CNS","volume":"4","author":"Eldar-Finkelman","year":"2011","journal-title":"Front. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.jfluchem.2021.109760_bib0045","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer\u2019s disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.jfluchem.2021.109760_bib0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/ni1221","article-title":"Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3","volume":"6","author":"Martin","year":"2005","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.jfluchem.2021.109760_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/026990599121827","article-title":"Subject Review: Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation","volume":"13","author":"Arciniegas","year":"1999","journal-title":"Brain Inj."},{"issue":"8","key":"10.1016\/j.jfluchem.2021.109760_bib0060","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrn2870","article-title":"GSK3 signalling in neural development","volume":"11","author":"Hur","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"23","key":"10.1016\/j.jfluchem.2021.109760_bib0065","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1089\/neu.2015.4177","article-title":"Inhibition of glycogen synthase Kinase-3: an emerging target in the treatment of traumatic brain injury","volume":"33","author":"Shim","year":"2016","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.jfluchem.2021.109760_bib0070","doi-asserted-by":"crossref","first-page":"8260","DOI":"10.3390\/molecules15118260","article-title":"Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT","volume":"15","author":"Hicks","year":"2010","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.jfluchem.2021.109760_bib0075","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1016\/j.bmcl.2005.08.037","article-title":"Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N\u2032-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3\u03b2 specific inhibitor for PET studies","volume":"15","author":"Vasdev","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.jfluchem.2021.109760_bib0080","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1021\/acsmedchemlett.5b00044","article-title":"Synthesis and initial in vivo studies with [11C]SB-216763: the first radiolabeled brain penetrative inhibitor of GSK-3","volume":"6","author":"Li","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"33","key":"10.1016\/j.jfluchem.2021.109760_bib0085","doi-asserted-by":"crossref","first-page":"9601","DOI":"10.1002\/anie.201603797","article-title":"Discovery of a highly selective glycogen synthase Kinase-3 inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: translation for PET neuroimaging","volume":"55","author":"Liang","year":"2016","journal-title":"Angew. Chemie Int. Ed."},{"issue":"21","key":"10.1016\/j.jfluchem.2021.109760_bib0090","doi-asserted-by":"crossref","first-page":"9600","DOI":"10.1021\/acs.jmedchem.9b01030","article-title":"Structural basis for achieving GSK-3\u03b2 inhibition with high potency, selectivity, and brain exposure for positron emission tomography imaging and drug discovery","volume":"62","author":"Bernard-Gauthier","year":"2019","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jfluchem.2021.109760_bib0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/acsmedchemlett.6b00405","article-title":"Development of [18F]Maleimide-based glycogen synthase Kinase-3\u03b2 ligands for positron emission tomography imaging","volume":"8","author":"Hu","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.jfluchem.2021.109760_bib0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.nucmedbio.2014.03.025","article-title":"Synthesis and evaluation of [11C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3\u03b2 (GSK-3\u03b2)","volume":"41","author":"Cole","year":"2014","journal-title":"Nucl. Med. Biol."},{"issue":"16","key":"10.1016\/j.jfluchem.2021.109760_bib0105","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.bmcl.2015.05.085","article-title":"Radiosynthesis and preliminary PET evaluation of glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) inhibitors containing [11C]methylsulfanyl, [11C]methylsulfinyl or [11C]methylsulfonyl groups","volume":"25","author":"Kumata","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.jfluchem.2021.109760_bib0110","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.bmcl.2019.01.033","article-title":"Radiosynthesis and evaluation of [11C]CMP, a high affinity GSK3 ligand","volume":"29","author":"Prabhakaran","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.jfluchem.2021.109760_bib0115","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1021\/acschemneuro.6b00376","article-title":"Radiosynthesis and in vivo evaluation of [11C]A1070722, a high affinity GSK-3 PET tracer in primate brain","volume":"8","author":"Prabhakaran","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.jfluchem.2021.109760_bib0120","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.bioconjchem.6b00163","article-title":"Synthesis of diverse 11C-Labeled PET radiotracers via direct incorporation of [11C]CO2","volume":"27","author":"Mossine","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"12","key":"10.1016\/j.jfluchem.2021.109760_bib0125","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1039\/C4SC02099E","article-title":"Late-stage [18F]fluorination: new solutions to old problems","volume":"5","author":"Brooks","year":"2014","journal-title":"Chem. Sci."},{"issue":"9","key":"10.1016\/j.jfluchem.2021.109760_bib0130","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/anie.201805501","article-title":"Chemistry for positron emission tomography: recent advances in 11C-, 18F-, 13N-, and 15O-labeling reactions","volume":"58","author":"Deng","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"issue":"6","key":"10.1016\/j.jfluchem.2021.109760_bib0135","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"issue":"23","key":"10.1016\/j.jfluchem.2021.109760_bib0140","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1021\/acs.orglett.5b02875","article-title":"Synthesis of [18F]Arenes via the copper-mediated [18F]Fluorination of boronic acids","volume":"17","author":"Mossine","year":"2015","journal-title":"Org. Lett."},{"issue":"4","key":"10.1016\/j.jfluchem.2021.109760_bib0145","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2967\/jnumed.117.197095","article-title":"Recent advances in 18F radiochemistry: a focus on B-18F, Si-18F, Al-18F, and C-18F radiofluorination via spirocyclic iodonium ylides","volume":"59","author":"Bernard-Gauthier","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.jfluchem.2021.109760_bib0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40336-020-00368-y","article-title":"Copper-mediated late-stage radiofluorination: five years of impact on preclinical and clinical PET imaging","volume":"8","author":"Wright","year":"2020","journal-title":"Clin. Transl. Imaging"},{"issue":"1","key":"10.1016\/j.jfluchem.2021.109760_bib0155","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41598-017-00110-1","article-title":"Development of customized [18F]Fluoride elution techniques for the enhancement of copper-mediated late-stage radiofluorination","volume":"7","author":"Mossine","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.jfluchem.2021.109760_bib0160","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/jlcr.2580270711","article-title":"Aryltrimethylammonium trifluoromethanesulfonates as precursors to aryl [18F]fluorides: improved synthesis of [18F]GBR-13119","volume":"27","author":"Haka","year":"1989","journal-title":"J. Labelled Comp. Radiopharm."},{"issue":"1","key":"10.1016\/j.jfluchem.2021.109760_bib0165","doi-asserted-by":"crossref","first-page":"11370","DOI":"10.1038\/s41598-019-47846-6","article-title":"A design of experiments (DoE) approach accelerates the optimization of copper-mediated 18F-Fluorination reactions of Arylstannanes","volume":"9","author":"Bowden","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Journal of Fluorine Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022113921000385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022113921000385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:21:18Z","timestamp":1778642478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022113921000385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":33,"alternative-id":["S0022113921000385"],"URL":"https:\/\/doi.org\/10.1016\/j.jfluchem.2021.109760","relation":{},"ISSN":["0022-1139"],"issn-type":[{"value":"0022-1139","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of GSK-3","name":"articletitle","label":"Article Title"},{"value":"Journal of Fluorine Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfluchem.2021.109760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109760"}}